Ahvie Herskowitz: Therapeutic Plasma Exchange as a Precision Cancer Weapon
Ahvie Herskowitz, Founder and Medical Director at Anatara Medicine, President at American College for Advancement in Medicine, shared a post on LinkedIn:
“Therapeutic Plasma Exchange (TPE) as a precision cancer weapon
A question I’ve been exploring in-depth over recent years: if the plasma itself is carrying oncogenic signaling molecules – tumor-derived exosomes, soluble PD-L1, senescence-associated secretory phenotypes, pro-inflammatory cytokines – can we intervene at the level of the blood’s liquid component and meaningfully shift the tumor microenvironment?
Therapeutic plasma exchange (TPE) has been used for decades in autoimmune conditions like thrombotic thrombocytopenic purpura, Guillain-Barré syndrome, and myasthenia gravis.
In recent studies, and what I presented at the Advanced Applications in Medical Practice (AAMP) conference this past fall, is the application of TPE in advanced cancer – specifically to strip the plasma of molecules that facilitate immune evasion and tumor proliferation.
The mechanism is more precise than people realize.
We’re not simply ‘cleaning the blood.’
We’re removing soluble PD-L1 and PD-L1-positive extracellular vesicles – the very molecules that inhibit programmed cell death in tumor cells.
Research published by Orme in 2020 documented that TPE clears these circulating checkpoints, and our clinical data has shown corresponding biomarker shifts that are difficult to dismiss: CRP reductions exceeding 90%, ferritin drops of nearly 90%, and complement cascade markers like C4a falling by over 80% in individual cases.
Those numbers represent a fundamental alteration of the inflammatory and immunosuppressive terrain in which advanced cancers operate.
The plasma carries everything – the good and the harmful.
Oncogenes, tumor-derived exosomes, autoantibodies, heavy metals, forever chemicals, and plastics.
When you exchange that plasma with ‘clean’ albumin, you’re essentially resetting the immunological landscape and giving the body’s surveillance systems a clearer field of operation.
This is terrain medicine applied at the molecular level. It’s not replacing conventional oncologic treatment – it’s addressing the environment in which those treatments either succeed or fail.
The TPE method we use at Anatara Medicine has been patented and published in placebo-controlled trials that show a reduction in circulating PD-L1 and PDL-1-positive inhibitors and its reversing effects for cognitive decline.
I believe TPE will become a standard adjunctive modality in integrative oncology within the next decade.
Right now, very few clinics are applying it in this context.
For colleagues in integrative and functional medicine: what’s your experience been with plasma-level interventions in complex cases?
Stay updated with Hemostasis Today.
-
Oct 9, 2026, 00:54Mary Catherine Moffett: Advancing Advocacy Together – Highlights from the Sanofi Bleeding Disorders Summit
-
Oct 9, 2026, 00:46Paris Margaritis: Assays vs Outcomes – Connecting FVIII Expression to Bleeding Phenotype in Hemophilia A
-
Oct 9, 2026, 00:39Rodrigo Arreola Diaz: The Rise of Concizumab for Hemophilia A and B
-
Oct 8, 2026, 23:27Shayan Mohammadmoradi: Happy to Be Back at the Midwest Platelet Conference for Its 20th Meeting
-
Oct 8, 2026, 23:18Lorena Arranz: Honoured to Contribute to the 6th Global MPN Symposium
-
Oct 8, 2026, 23:06Denis Oduor: Serving Citizens and Saving Lives Through Blood Donation During National Customer Service Week 2026
-
Oct 8, 2026, 22:51Jan Hartmann: Speaking on Global Trends in Plasma Collection at the 50th Meeting of the Japanese Society of Blood Services
-
Oct 8, 2026, 22:49Akshat Jain: Proud to Announce the Publication of Advances in Sickle Cell Disease
-
Oct 8, 2026, 22:49Ed Shovelin: Extending the Platelet Aggregation Testing Window to 72 Hours